Results 81 to 90 of about 8,911,089 (208)

Major adverse cardiovascular events, intracerebral haemorrhage, and GI bleeding before and after PS matching.

, 2019
Major adverse cardiovascular events, intracerebral haemorrhage, and GI bleeding before and after PS matching.
Chaur-Jong Hu (125228), Chih-Hsin Muo (291210), You-Chia Chen (7325630), Dean Wu (4003010), Chung Y. Hsu (7255547), Amelia Nur Vidyanti (7325627), Lung Chan (3913255), Cheng-Li Lin (388859)   +7 more
core   +1 more source

Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon‐Like Peptide‐1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background To evaluate the association between tirzepatide use and 1‐year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP‐1 (glucagon‐like peptide‐1) receptor ...
Jheng‐Yan Wu, Keng‐Wei Lee, Chia‐Li Kao, Kuo‐Chuan Hung, Tsung Yu, Yu‐Min Lin   +5 more
doaj   +1 more source

Association of Lipoprotein(a) With Major Adverse Cardiovascular Events Across hs-CRP

JACC: Advances
Background: Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. The relationship between Lp(a) and major adverse cardiovascular events (MACE) in the context of high-sensitivity C-reactive protein (hs-CRP ...
Pamela L. Alebna, MD, MPH, Chin Yip Han, MD, Mathew Ambrosio, MS, Gwyneth Kong, MD, John W. Cyrus, BA, Kayla Harley, BA, Le Kang, PhD, Aeron M. Small, MD, MTR, Parag Chevli, MBBS, MS, Harpreet Bhatia, MD, MAS, Nicholas Chew, MD, Fadi N. Salloum, PhD, Dave L. Dixon, PharmD, Antonio Abbate, MD, PhD, Pradeep Natarajan, MD, MMSc, Michael D. Shapiro, DO, MCR, Anurag Mehta, MD   +16 more
doaj   +1 more source

Cox regression analysis for major adverse cardiovascular events, all cause mortality and cardiovascular mortality.

, 2014
Abbreviation as table 1; CI: confidence interval.Cox regression analysis for major adverse cardiovascular events, all cause mortality and cardiovascular mortality.
Hung-I Yeh (378406), Min-I Su (642751), Cheng-Ting Tsai (642752), Chun-Yen Chen (642753)   +3 more
core   +1 more source

Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study

BMJ Medicine
Objective To examine the effects of fish oil supplements on the clinical course of cardiovascular disease, from a healthy state to atrial fibrillation, major adverse cardiovascular events, and subsequently death.Design Prospective cohort study.Setting UK
Ge Chen, Zilong Zhang, Michael G Vaughn, Gregory YH Lip, Shiyu Zhang, Hualiang Lin, Zhengmin (Min) Qian, Chuangshi Wang, Junguo Zhang, Hannah E Aaron   +9 more
doaj   +1 more source

Influence factors and risk assessment model of hyperuricemia complicated with major adverse cardiovascular events [PDF]

Jichu yixue yu linchuang
Objective To explore the factors associated with major adverse cardiovascular events (MACE) in patients with hyperuricemia and to establish a corresponding risk assessment model.
GUO Limin, SHI Li, SHE Qimei, GU Guiyan, LI Ailing
doaj   +1 more source

The cumulative probability of (A) major adverse cardiovascular events (MACE) or all-cause mortality (B) major adverse cardiovascular events (MACE) (C) all-cause mortality according to Angiopoietin-2 quintiles.

, 2015
The cumulative probability of (A) major adverse cardiovascular events (MACE) or all-cause mortality (B) major adverse cardiovascular events (MACE) (C) all-cause mortality according to Angiopoietin-2 quintiles.
Yi-Chun Tsai (106520), Hung-Tien Kuo (106539), Su-Chu Lee (639335), Shang-Jyh Hwang (5312), Hung-Chun Chen (106543), Mei-Chuan Kuo (106525), Chee-Siong Lee (284542), Yi-Wen Chiu (106535)   +7 more
core   +1 more source

Risk of Major Adverse Cardiovascular Events with JAK inhibitors in Alopecia Areata, a Systematic Review

, 2022
Systematic review of major adverse cardiovascular events in alopecia areata patients treated with janus kinase inhibitors.THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE.
Kincaid, C (via Mendeley Data), Kincaid, Colin   +1 more
core   +1 more source

Major adverse cardiovascular events (MACE)-free survival rate between resistant hypertension (RH) and non-RH groups.

, 2014
Major adverse cardiovascular events (MACE)-free survival rate between resistant hypertension (RH) and non-RH groups.
El-Wui Loh (608396), Jin-Long Huang (599641), Tsu-Juey Wu (459389), Yu-Cheng Hsieh (599643), Chen-Ying Hung (608395), Ching-Heng Lin (512565), Kuo-Yang Wang (599645)   +6 more
core   +1 more source

Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. [PDF]

, 2007
BACKGROUND: Adverse drug reactions (ADRs) are a frequent cause of mortality and morbidity to patients worldwide, with great associated costs to the healthcare providers including the NHS in England.
Majeed, Azeem, Patel, M, Car, J, Molokhia, Mariam, Mariam Molokhia, Janakan Srishanmuganathan, Patel, H, Bell, Derek, Car, Josip; id_orcid, Srishanmuganathan, Janakan, Car, Josip, Majeed, A, Mitesh Patel, Patel, Hitesh, Josip Car, Bell, D, Molokhia, M, Patel, Mitesh, Derek Bell, Srishanmuganathan, J, Hitesh Patel, Azeem Majeed   +21 more
core   +2 more sources